Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut-X-001 in Alzheimer's Disease (ESCAPE-AD)
NCT07591727Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2026
- Primary completion
- May 2027
01
Overview
Phase 2, randomised, double-blind trial of Gut-X-001 in Alzheimer's disease (AD) (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 at 6 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Gut-X-001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07591727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591727.